SAVE THE DATE – NORDIC NANOVECTOR CAPITAL MARKETS DAY
Oslo, Norway, 20 April 2016
Nordic Nanovector ASA (OSE: NANO) is pleased to announce that it will host a Capital Markets Day onTuesday 31 May 2016 in Oslo. The program will begin at 08:30 CEST, followed by lunch. A formal invitation, including the full programme and registration details, will be distributed at a later stage.
###
For further information, please contact:
Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARCs) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with the first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its pipeline of ARCs to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.
Source: Nordic Nanovector
